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Low doses of inhaled corticosteroids control more
asthma outcomes to a greater extent than any other
asthma therapy in the vast majority of patients and all
international guidelines now recommend inhaled corti-
costeroids as first line treatment in all children who
require regular controller therapy for asthma. This para-
digm shift in asthma management is based on solid evi-
dence from several controlled trials. Whenever these
guideline recommendations are implemented and fol-
lowed health-care statistics improve markedly in the
society. However, several studies have found that often
the guideline recommendations are not being followed.
There are several reasons for this, including concerns
about the safety of long-term use of these agents, parti-
c u l a r l yi nc h i l d r e n .T h e s ec o n c e r n sm a i n l ys t e mf r o m
the findings in short-term studies assessing the effects
of inhaled corticosteroids on lower leg growth rate or
the hypothalamic–pituitary–adrenal axis or markers of
bone formation and degradation. However, the clinical
relevance of findings in such studies for long-term treat-
ment is unknown and uncertainty exists regarding the
predictive value of changes in cortisol levels and clini-
cally relevant changes in long-term growth or bone
density.
A recent review on the long-term safety of ICS found
that there was some evidence of a small decrease in
statural growth rate during the beginning of inhaled
corticosteroid therapy. This effect was more marked at
daily doses above 200 µg and did not apply to all treat-
ment regimens. Studies examining final attained adult
height found no difference between patients treated
with inhaled corticosteroids and those receives non-
steroidal therapy. None of the studies investigating
effects on bone mineral density found any adverse
effects of inhaled corticosteroid therapy. Finally,
recommended doses of inhaled corticosteroids gener-
ally had little or no effect on plasma or urine cortisol
levels versus non-steroidal therapy. In contrast, use of
short courses of oral steroids (which is common prac-
tice in many countries) has been found to increase the
risk of fracture in children. The review concluded that
recommended doses of inhaled corticosteroids can be
administered to children for the long-term manage-
ment of asthma with minimal risk of clinically relevant
adverse effects. This conclusion is supported findings
in a study on peak bone mineral density and risk of
fracture in 275 ICS treated patients and 161 healthy
siblings. The asthma patients had been treated with
ICS for 2-22 years (mean 13.7 years) at a mean daily
dose of 350 µg ICS. In adulthood there was no statisti-
cally significant difference between BMD Z-score in
ICS treated children (mean Z-score 0.29) and the z-
score of their healthy siblings (mean Z-score = 0.34).
Moreover, in the asthma group no statistically signifi-
cant difference was seen between BMD Z –score at
study entry (-0.10) and in adulthood (+0.04).
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